AN2 Therapeutics, Inc. (ANTX) Key Statistics & Financial Ratios

AN2 Therapeutics, Inc. (ANTX) — Price $5.34 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for AN2 Therapeutics, Inc. (ANTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.

Stock Data

Price$5.34
Market Cap$192M
Enterprise Value$148.7M
Beta-1.32
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-5.01
Price / Book3.16
P/S0.00
EV/EBITDA-3.96
EV/Sales0.00
EV/FCF-4.85
P/FCF-6.29
Earnings Yield-15.12%
FCF Yield-15.89%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-53.52%
Return on Assets-44.41%
Return on Invested Capital-51.01%
Return on Capital Employed-51.01%

Financial Health

Current Ratio14.32
Quick Ratio14.32
Cash Ratio7.94
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA1.18
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share1.70
Cash per share1.75
FCF per share-0.69
Tangible Book Value per share1.70
Dividend per share0.00

Related companies: BOLD · IBIO · INTS · ITRM · NXTC · PLUR · PSTV

Explore sector: Healthcare · Biotechnology

More sections of ANTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks